The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover weight loss drugs, the Centers for Medicare and Medicaid Services said in a filing published Friday by the agency. A CMS spokesperson said the agency now believes that finalizing the proposal "is not appropriate at this time."

The Trump administration canceled a Biden-era plan on Friday that would have made Ozempic and other weight-loss drugs available on Medicare and Medicaid and expanded access to them for millions of Ame

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access to weight-loss drugs paid for Medicare and Medicaid.